Entera Bio Ltd
ENTX2.040USD
+0.090+4.62%
Market hours （ET）Quotes delayed by 15 min
92.66MMarket Cap
LossP/E TTM
More Details of Entera Bio Ltd Company
Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Company Info
Ticker SymbolENTX
Company nameEntera Bio Ltd
IPO dateJun 28, 2018
CEOMs. Miranda Jayne Toledano
Number of employees18
Security typeOrdinary Share
Fiscal year-endJun 28
AddressHadassah / Jerusalem Bio
CityJERUSALEM
Stock exchangeNASDAQ Capital Market Consolidated
CountryIsrael
Postal code9112002
Phone97225327151
Websitehttps://enterabio.com/
Ticker SymbolENTX
IPO dateJun 28, 2018
CEOMs. Miranda Jayne Toledano
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Mr. Ron Abraham Mayron
Mr. Ron Abraham Mayron
Independent Director
Independent Director
--
--
Ms. Dana Yaacov-Garbeli
Ms. Dana Yaacov-Garbeli
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Roger J. Garceau, M.D.
Dr. Roger J. Garceau, M.D.
Director
Director
--
--
Dr. Hillel Galitzer
Dr. Hillel Galitzer
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Chairman of the Board
Independent Chairman of the Board
324.96K
--
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Chief Executive Officer, Director
Chief Executive Officer, Director
291.45K
+163.16%
Mr. Sean Ellis
Mr. Sean Ellis
Independent Director
Independent Director
134.73K
--
Ms. Haya Taitel
Ms. Haya Taitel
Independent Director
Independent Director
64.65K
--
Mr. Yonatan Malca
Mr. Yonatan Malca
Independent Director
Independent Director
47.26K
--
Mr. Gerald M. (Jerry) Ostrov
Mr. Gerald M. (Jerry) Ostrov
Independent Director
Independent Director
46.94K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jul 17
Updated: Thu, Jul 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.94%
OPKO Health Inc
8.50%
D.N.A Biomedical Solutions, Ltd.
8.21%
Point72 Asset Management, L.P.
5.93%
Centillion Fund Inc
5.27%
Other
59.14%
Shareholders
Shareholders
Proportion
Knoll Capital Management, LLC
12.94%
OPKO Health Inc
8.50%
D.N.A Biomedical Solutions, Ltd.
8.21%
Point72 Asset Management, L.P.
5.93%
Centillion Fund Inc
5.27%
Other
59.14%
Shareholder Types
Shareholders
Proportion
Corporation
21.99%
Hedge Fund
21.33%
Individual Investor
2.44%
Investment Advisor
0.70%
Research Firm
0.07%
Investment Advisor/Hedge Fund
0.05%
Venture Capital
0.02%
Other
53.41%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
44
20.97M
46.14%
-173.92K
2025Q1
48
20.87M
47.30%
+2.99M
2024Q4
45
14.59M
39.63%
+276.18K
2024Q3
44
12.66M
34.61%
+129.89K
2024Q2
43
12.40M
34.23%
+1.30M
2024Q1
39
11.33M
31.94%
+147.25K
2023Q4
38
10.84M
34.31%
+2.50M
2023Q3
40
9.31M
32.31%
-70.93K
2023Q2
42
9.22M
32.01%
-186.20K
2023Q1
42
9.45M
32.81%
-129.12K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Knoll Capital Management, LLC
5.88M
12.94%
--
--
Mar 31, 2025
OPKO Health Inc
3.87M
8.5%
+180.00K
+4.88%
May 08, 2025
D.N.A Biomedical Solutions, Ltd.
3.73M
8.21%
--
--
May 08, 2025
Point72 Asset Management, L.P.
2.70M
5.93%
-4.32K
-0.16%
Mar 31, 2025
Centillion Fund Inc
2.40M
5.27%
--
--
May 08, 2025
Schonfeld Strategic Advisors LLC
599.16K
1.32%
-33.16K
-5.24%
Mar 31, 2025
Parkman Healthcare Partners LLC
439.63K
0.97%
+25.90K
+6.26%
Mar 31, 2025
Lieberman (Gerald M)
324.96K
0.71%
--
--
May 08, 2025
Toledano (Miranda Jayne)
110.75K
0.24%
--
--
May 08, 2025
Northern Trust Global Investments Limited
198.83K
0.44%
-13.65K
-6.42%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
